BLASUBCUTANEOUSINJECTABLE
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy) by Bristol Myers Squibb is programmed death receptor-1-directed antibody interactions [moa]. First approved in 2024.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPDIVO QVANTIG is a subcutaneous formulation combining nivolumab (a PD-1 checkpoint inhibitor) with hyaluronidase to enable rapid subcutaneous administration. It works by blocking programmed death receptor-1 interactions to reinvigorate anti-tumor immune responses. The product represents a delivery innovation for an established immunotherapy mechanism.
Growth
Early-stage growth product with emerging market opportunity; small but expanding commercial teams expected as uptake accelerates.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Endoglycosidase
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on OPDIVO QVANTIG at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.